Genome Medicine (Dec 2023)

Personalized tumor combination therapy optimization using the single-cell transcriptome

  • Chen Tang,
  • Shaliu Fu,
  • Xuan Jin,
  • Wannian Li,
  • Feiyang Xing,
  • Bin Duan,
  • Xiaojie Cheng,
  • Xiaohan Chen,
  • Shuguang Wang,
  • Chenyu Zhu,
  • Gaoyang Li,
  • Guohui Chuai,
  • Yayi He,
  • Ping Wang,
  • Qi Liu

DOI
https://doi.org/10.1186/s13073-023-01256-6
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Background The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment. Methods Here, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC provides a workable solution to stratify individual patient samples based on quantitative evaluation of their personalized immune microenvironment with single-cell RNA sequencing and maximize the translational potential of in vitro cellular response to unify the identification of synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors to boost immunotherapy from a large collection of small molecules and drugs, and finally prioritize them for personalized clinical use based on bipartition graph optimization. Results We apply comboSC to publicly available 119 single-cell transcriptome data from a comprehensive set of 119 tumor samples from 15 cancer types and validate the predicted drug combination with literature evidence, mining clinical trial data, perturbation of patient-derived cell line data, and finally in-vivo samples. Conclusions Overall, comboSC provides a feasible and one-stop computational prototype and a proof-of-concept study to predict potential drug combinations for further experimental validation and clinical usage using the single-cell transcriptome, which will facilitate and accelerate personalized tumor treatment by reducing screening time from a large drug combination space and saving valuable treatment time for individual patients. A user-friendly web server of comboSC for both clinical and research users is available at www.combosc.top . The source code is also available on GitHub at https://github.com/bm2-lab/comboSC .

Keywords